في دراسه على 285 مريضًا وجد الباحثون ان ٤٠٪ من المرضى انتجو الأجسام المضادة من نوع IgM في الأسبوع الأول بعد الاصابه بCOVID-19 ، إلا أن هذا الرقم زاد إلى 95 بالمائة تقريبًا بعد أسبوعين. وأنتج جميع هؤلاء المرضى أيضًا الأجسام المضادة IgG. https://t.co/tSPxcm5gk1
Antibody responses to SARS-CoV-2 in patients with COVID-19.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Apr 2020 – Jun 2025Where it's discussed
-
X / Twitter141 posts
-
News114 articles
-
Facebook30 posts
-
Blogs18 articles
-
Reddit10 posts
-
YouTube3 videos
-
Bluesky2 posts
AI synopsis
What people are saying
Several discussions highlight the study's claim that 100% of patients tested positive for IgG antibodies within 19 days of symptom onset. Users express curiosity about the implications of these findings, discussing how the timing of antibody responses can affect immunity and recovery. The use of terms like 'critical for survival' and the emphasis on diagnosing asymptomatic cases reflect a tone of urgency and excitement, underscoring the significance of the research in shaping public health strategies during the pandemic.
Overall, many discussions express a positive view towards the findings, indicating general support for the study's conclusions.
The majority of participants show high engagement due to the relevance of antibody responses in understanding COVID-19.
Some discussions delve into specific aspects of the study and share related research, showing a moderate level of analytical engagement.
Participants perceive the findings as significant, suggesting that the research could influence future diagnostic approaches for COVID-19.
Abstract in brief
- The study analyzed the antibody responses of 285 COVID-19 patients, finding that all tested positive for IgG within 19 days of symptom onset.
- IgG and IgM antibodies either developed at the same time or one after the other, reaching stable levels within 6 days post-seroconversion.
- Serological tests could aid in diagnosing COVID-19, especially in cases with negative RT-PCR results and in detecting asymptomatic infections.
Top posts
Most liked on X and Bluesky●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID-19 https://t.co/FgFOMDxNq0
Antibody Responses to SARS-CoV-2 in Patients With COVID-19 https://t.co/han1QKUFxu
Respuestas de Anticuerpos al SARS-CoV-2 en pacientes con COVID-19. https://t.co/dZ7DRSY5nj https://t.co/iOONvrwU5o
ANTICUERPOS. En este estudio Si se muestra que al menos casi todos los@pacientes con COVID-19 SEVERO desarrollan anticuerpos. Falta un trecho hasta un VERDADERO TEST RÁPIDO. Antibody responses to SARS-CoV-2 in patients with COVID-19 | Nature Medicine https://t.co/r34ORz73W2
Los IgM son los primeros en aparecer en una infección y los IgG suelen aparecer un poco más tarde de una infección aguda. Para SARS-CoV-2 encontraron que la producción de estos Ac es de 2-3 semanas, aun faltan más que garanticen la protección de éstos https://t.co/dNtW0F4XPt https://t.co/kCubFcZ4JC
All mentions
Understanding Plasma Therapy for COVID-19 Treatment
This video explores plasma therapy and its role in treating COVID-19. We analyze antibody responses in patients, highlighting key findings that all participants tested positive for IgG within 19 days of symptoms…
Antibody Responses in COVID-19 Patients: Key Findings
This video explores the antibody responses to SARS-CoV-2 in 285 COVID-19 patients, revealing that all tested positive for IgG within 19 days of symptom onset. Serological tests may assist in diagnosing suspected cases…
Can Covid 19 Confer Protective Immunity?
Open Access UCL Research: B cell and antibody responses to SARS-CoV-2 in people living with HIV discovery.ucl.ac.uk/id/eprint/10...
On this day in COVID history, May 11, 2021: Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival - Nature Communications Source: Nature https://www.nature.com/articles/s41467-021-22958-8
@TierraHenson @groin_hammer @JCDeardeuff @BurgerLab12 @mcfunny @JTylerHagen @rw_christian @villagerssn @F250Roush @barryjohnreid21 @pawley_robert @brave3564445 @moy_barry @JustPlaying2Win @wjack76995 @JoeCoyle101 @ADevotedYogi @Kathmarval @Chris_F_Carson @MrTI63257722 @TracyMMPohill @Bebert701 @andylumm @temple_surly @BuzzKent1776 @TwoCoconutHusks @cappsie @dmatt59 @LWSmith15 @ghoppe @GeoffSchuler @ShawnWo78307528 @MRobovsky @SkepticSplinter @ChrisJohnsonMD @OceanAteMyPhone @johnnyutah66623 @JSAHolmes @WhoCares011813 @Amber84280581 @SwaledaleMutton @Craig12940777 @Crippsy1969 @bigmack600 I’m not aware of any studies claiming some won’t develop antibodies, nor could I find any. Please include if you have. It’s still debated how long resistance lasts, yes. A relatively small study but still relevant I believe: https://t.co/Ndxm1tJDKK https://t.co/ODQLKN83e9
Longitudinal Change of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus Disease 2019. J. Infect. Dis. 2020, 222, 183–188. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 2020, 26, 845–848.
@momsyw @betawave74 @GuyOn2Wheelz @BowinnMa https://t.co/VygNEkvfgC https://t.co/oA5m2RiSyF
Antibody responses to SARS-CoV-2 in patients with COVID-19 | Nature Medicine https://t.co/hf7CD49DG6
RT @mtmdphd: Antibody responses to SARS-CoV-2 in patients with COVID-19 [Apr 29, 2020] Long et al. @NatureMedicine https://t.co/NMeoxyKtfM…
Antibody responses to SARS-CoV-2 in patients with COVID-19 [Apr 29, 2020] Long et al. @NatureMedicine https://t.co/NMeoxyKtfM #COVID19 #CCC19 HT @ADesaiMD n=285. Within 19 days after symptom onset, 100% of patients tested positive for antiviral IgG https://t.co/5aqcZomOxm
@RAKemal @lendirgyarados izin nimbrung sekalian sharing, tadi ikut webinar molekular infectious disease. Menurut narasumbernya Sarscov2 agak beda, IgG dan IgM di meningkatnya bersamaan dan serokonversinya juga nggak seragam, nggak selalu IgM didahului IgG, cmiiw https://t.co/ZdQA7Umafu
Natureの論文 Antibody responses to SARS-CoV-2 in patients with COVID-19 https://t.co/HWAy2wrLhp
RT @hichachu: 図3 SARS-CoV-2感染の動態の図解。Ab応答の時間経過は参考文献に基づいている。 Long, Q., Liu, B., Deng, H. et al. Antibody responses to SARS-CoV-2 in patients…
RT @hichachu: 図3 SARS-CoV-2感染の動態の図解。Ab応答の時間経過は参考文献に基づいている。 Long, Q., Liu, B., Deng, H. et al. Antibody responses to SARS-CoV-2 in patients…
RT @hichachu: 図3 SARS-CoV-2感染の動態の図解。Ab応答の時間経過は参考文献に基づいている。 Long, Q., Liu, B., Deng, H. et al. Antibody responses to SARS-CoV-2 in patients…
図3 SARS-CoV-2感染の動態の図解。Ab応答の時間経過は参考文献に基づいている。 Long, Q., Liu, B., Deng, H. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 26, 845–848 (2020). https://t.co/QtKsRnWAts https://t.co/oD5mLVlKfy
RT @bioworldbg: Every question arising in common man's mind related to plasma therapy for covid-19 are answered in this video: Link: https:…
Every question arising in common man's mind related to plasma therapy for covid-19 are answered in this video: Link: https://t.co/V4vmWtTudh Thank you @PMOIndia @ArvindKejriwal @narendramodi for introducing and promoting this therapy. #delhifghtscorona #IndiaFightsCoronavirus https://t.co/hsK5AXLUbf
RT @mtmdphd: Antibody responses to SARS-CoV-2 in patients with COVID-19 [Apr 29, 2020] Long et al. @NatureMedicine https://t.co/NMeoxyKtfM…
RT @mtmdphd: Antibody responses to SARS-CoV-2 in patients with COVID-19 [Apr 29, 2020] Long et al. @NatureMedicine https://t.co/NMeoxyKtfM…
Antibody responses to SARS-CoV-2 in patients with COVID-19 [Apr 29, 2020] Long et al. @NatureMedicine https://t.co/NMeoxyKtfM #COVID19 #CCC19 HT @ADesaiMD n=285. Within 19 days after symptom onset, 100% of patients tested positive for antiviral IgG https://t.co/0ZyoV3f4kZ
RT @mtmdphd: Antibody responses to SARS-CoV-2 in patients with COVID-19 [Apr 29, 2020] Long et al. @NatureMedicine https://t.co/NMeoxyKtfM…
Antibody responses to SARS-CoV-2 in patients with COVID-19 [Apr 29, 2020] Long et al. @NatureMedicine https://t.co/NMeoxyKtfM #COVID19 #CCC19 HT @ADesaiMD n=285. Within 19 days after symptom onset, 100% of patients tested positive for antiviral IgG
Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845-848. doi:10.1038/s41591-020-0897-1
Another question I’m curious about? Given data and the nature of corona viruses, are we at the point of assumed immunity for those recovered from the infection? Does that level of immunity depend on severity of infection? https://t.co/LPXS4M7GP8 (end)
Antibody responses to SARS-CoV-2 in patients with COVID-19 https://t.co/Fsctjn4UQD
RT @PopSci: Frustratingly, we don’t know yet! A study from April suggests basically everyone who gets infected produces antibodies within w…
Frustratingly, we don’t know yet! A study from April suggests basically everyone who gets infected produces antibodies within weeks, but no data exists on how long those antibodies might stick around or what level of protection they offer. -SC #AskPopSci https://t.co/ULgs0K3pTm https://t.co/eW88pSR3E9
RT @Luis_I_Gomez: @RafaelTimermans @Godivaciones @luluariass Más. Lo normal es que prácticamente todo el que ha tenido coronavirus haya des…
@RafaelTimermans @Godivaciones @luluariass Más. Lo normal es que prácticamente todo el que ha tenido coronavirus haya desarrollado anticuerpos: https://t.co/K1lBDwhwUT
@ark_610 Çok büyük örneklemler yok. Küçük olanlar da covid hastalarında sonradan %100-%95 arasında antikor gözlemlendiğini söylüyor. https://t.co/lcZiorgBkr https://t.co/Gkgtd14xDC
Referências: 1Katzelnick, L. C. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 358, 929–932 (2017). 2 Long, Q.-X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med.
Antibody responses to SARS-CoV-2 in patients with COVID-19 | Nature Medicine https://t.co/tddcahW64S
RT @ParsonageMaria: Antibody responses to SARS-CoV-2 in patients with COVID-19 | Nature Medicine @ARNS_UK @WirralU @r_NWCN https://…
@nikkan_n 2番目の抗体が形成されるであろう日数のグラフのことですか? これもコロナ19のグラフです。もちろん、現時点での知見ではありますが。 https://t.co/qwdqGnQcdW
RT @ParsonageMaria: Antibody responses to SARS-CoV-2 in patients with COVID-19 | Nature Medicine @ARNS_UK @WirralU @r_NWCN https://…
Antibody responses to SARS-CoV-2 in patients with COVID-19 | Nature Medicine @ARNS_UK @WirralU @r_NWCN https://t.co/AU61bkPqZ3
@RichardOdle @DrMichaelMosley "The team found that, WITH THE EXCEPTION of one woman and her daughter, the patients produced specific antibodies against SARS-CoV-2 within 20 days of their first symptoms of COVID-19." https://t.co/tVShSy6GDx Study https://t.co/AJevTDMsZU
@Pravduh15 @justin_hart I see. Here it is. I would not say it’s conclusive. But it’s good because it provides evidence In support. https://t.co/eF6aqEb2xN
3) The authors rightly confine themselves to conclusions about diagnostic uses of antibody tests to augment antigen tests & for identification of asymptomatic cases https://t.co/DT3fb2eHws
2) Please also note that the Nature paper on human antibody response to #Covid19 (with 285 subjects) did not test virus neutralisation by antibodies, so no conclusion is drawn about immunity https://t.co/DT3fb2eHws #Covid19UK #HerdImmunity #Covid_19 #CoronaUK #OurNHSPeople https://t.co/oFkCi9L4xo
RT @HalimaAlbulushi: في دراسه على 285 مريضًا وجد الباحثون ان ٤٠٪ من المرضى انتجو الأجسام المضادة من نوع IgM في الأسبوع الأول بعد الاصابه ب…
Antibody responses to SARS-CoV-2 in patients with COVID-19. - PubMed - NCBI https://t.co/FIpBHKhmxZ
Antibody responses to SARS-CoV-2 in patients with COVID-19. - PubMed - NCBI In Nature Medicine. In which I was proud to write many early news (as a journalist) stories when I lived in Washington DC. https://t.co/8je7XXhpQF
Evidence is starting to trickle in about #SARSCoV2 post-infection immunity. Two papers: Antibody Responses to SARS-CoV-2 in Patients With COVID-19 https://t.co/C05YNSfsmY COVID-19 and Post Infection Immunity Limited Evidence, Many Remaining Questions https://t.co/KTjOltvpul
@globalhlthtwit @syrpis This report said most infected people were found to have developed antibodies after having C19 https://t.co/7SsUTc0ycY
Antibody responses to #SARS-CoV-2 in patients with #COVID-19 https://t.co/c3JGZ8xmTY
RT @RegaCarlos: ANTICUERPOS. En este estudio Si se muestra que al menos casi todos los@pacientes con COVID-19 SEVERO desarrollan anticuerpo…
RT @RegaCarlos: ANTICUERPOS. En este estudio Si se muestra que al menos casi todos los@pacientes con COVID-19 SEVERO desarrollan anticuerpo…
RT @RegaCarlos: ANTICUERPOS. En este estudio Si se muestra que al menos casi todos los@pacientes con COVID-19 SEVERO desarrollan anticuerpo…
RT @RegaCarlos: ANTICUERPOS. En este estudio Si se muestra que al menos casi todos los@pacientes con COVID-19 SEVERO desarrollan anticuerpo…
RT @RegaCarlos: ANTICUERPOS. En este estudio Si se muestra que al menos casi todos los@pacientes con COVID-19 SEVERO desarrollan anticuerpo…
ANTICUERPOS. En este estudio Si se muestra que al menos casi todos los@pacientes con COVID-19 SEVERO desarrollan anticuerpos. Falta un trecho hasta un VERDADERO TEST RÁPIDO. Antibody responses to SARS-CoV-2 in patients with COVID-19 | Nature Medicine https://t.co/r34ORz73W2
Antibody responses to SARS-CoV-2 in patients with COVID-19. Brief communication @naturemethods https://t.co/8QqFgStugw #research #science #immunology #meded
Antibody responses to SARS-CoV-2 in patients with COVID-19 | Nature Medicine https://t.co/K7Ua9hSOec
RT @HalimaAlbulushi: في دراسه على 285 مريضًا وجد الباحثون ان ٤٠٪ من المرضى انتجو الأجسام المضادة من نوع IgM في الأسبوع الأول بعد الاصابه ب…
RT @HalimaAlbulushi: في دراسه على 285 مريضًا وجد الباحثون ان ٤٠٪ من المرضى انتجو الأجسام المضادة من نوع IgM في الأسبوع الأول بعد الاصابه ب…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @HalimaAlbulushi: في دراسه على 285 مريضًا وجد الباحثون ان ٤٠٪ من المرضى انتجو الأجسام المضادة من نوع IgM في الأسبوع الأول بعد الاصابه ب…
RT @HalimaAlbulushi: في دراسه على 285 مريضًا وجد الباحثون ان ٤٠٪ من المرضى انتجو الأجسام المضادة من نوع IgM في الأسبوع الأول بعد الاصابه ب…
RT @HalimaAlbulushi: في دراسه على 285 مريضًا وجد الباحثون ان ٤٠٪ من المرضى انتجو الأجسام المضادة من نوع IgM في الأسبوع الأول بعد الاصابه ب…
「 ウイルスのどの部分の抗体なのかによって微妙に異なりますが、新型コロナウイルスでは発症から概ね2週間くらいで8割の人が、概ね3週間くらいでほぼ全ての人がIgMまたはIgGが陽性になります(https://t.co/JZBAKGlixl)。 」
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @HalimaAlbulushi: في دراسه على 285 مريضًا وجد الباحثون ان ٤٠٪ من المرضى انتجو الأجسام المضادة من نوع IgM في الأسبوع الأول بعد الاصابه ب…
RT @HalimaAlbulushi: في دراسه على 285 مريضًا وجد الباحثون ان ٤٠٪ من المرضى انتجو الأجسام المضادة من نوع IgM في الأسبوع الأول بعد الاصابه ب…
RT @HalimaAlbulushi: في دراسه على 285 مريضًا وجد الباحثون ان ٤٠٪ من المرضى انتجو الأجسام المضادة من نوع IgM في الأسبوع الأول بعد الاصابه ب…
RT @HalimaAlbulushi: في دراسه على 285 مريضًا وجد الباحثون ان ٤٠٪ من المرضى انتجو الأجسام المضادة من نوع IgM في الأسبوع الأول بعد الاصابه ب…
RT @HalimaAlbulushi: في دراسه على 285 مريضًا وجد الباحثون ان ٤٠٪ من المرضى انتجو الأجسام المضادة من نوع IgM في الأسبوع الأول بعد الاصابه ب…
RT @HalimaAlbulushi: في دراسه على 285 مريضًا وجد الباحثون ان ٤٠٪ من المرضى انتجو الأجسام المضادة من نوع IgM في الأسبوع الأول بعد الاصابه ب…
RT @HalimaAlbulushi: في دراسه على 285 مريضًا وجد الباحثون ان ٤٠٪ من المرضى انتجو الأجسام المضادة من نوع IgM في الأسبوع الأول بعد الاصابه ب…
RT @HalimaAlbulushi: في دراسه على 285 مريضًا وجد الباحثون ان ٤٠٪ من المرضى انتجو الأجسام المضادة من نوع IgM في الأسبوع الأول بعد الاصابه ب…
في دراسه على 285 مريضًا وجد الباحثون ان ٤٠٪ من المرضى انتجو الأجسام المضادة من نوع IgM في الأسبوع الأول بعد الاصابه بCOVID-19 ، إلا أن هذا الرقم زاد إلى 95 بالمائة تقريبًا بعد أسبوعين. وأنتج جميع هؤلاء المرضى أيضًا الأجسام المضادة IgG. https://t.co/tSPxcm5gk1
RT @MonsieurQFB: Los IgM son los primeros en aparecer en una infección y los IgG suelen aparecer un poco más tarde de una infección aguda.…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
"Antibody responses to SARS-CoV-2 in patients with COVID-19" https://t.co/N0ti9BSVNy
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
In 285 patients with COVID-19, within 19 days after symptom onset, 100% of patients tested positive for antiviral IgG. Antibody responses to SARS-CoV-2 in patients with COVID-19 | Nature https://t.co/cERtNGdLGy
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
RT @influenzer3: ●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID…
●MCLIA法による抗体測定では285例の検証で全例がIgG陽性となる →この検討でもIgGの高値と重症度の相関性が示されています。 Antibody responses to SARS-CoV-2 in patients with COVID-19 https://t.co/FgFOMDxNq0
Los IgM son los primeros en aparecer en una infección y los IgG suelen aparecer un poco más tarde de una infección aguda. Para SARS-CoV-2 encontraron que la producción de estos Ac es de 2-3 semanas, aun faltan más que garanticen la protección de éstos https://t.co/dNtW0F4XPt https://t.co/kCubFcZ4JC
RT @JezidMiranda: Antibody responses to SARS-CoV-2 in patients with COVID-19. Serological testing will be helpful for the diagnosis of susp…
Nature medicine COVID rapid test. Antibody Responses to SARS-CoV-2 in Patients With COVID-19 https://t.co/QHreo4Qgc4
RT @S_Ordibehesht: @thehill Antibody responses to SARS-CoV-2 in patients with COVID-19 | Quan-Xin Long, et al. @NatureMedicine 29 April 202…
@thehill Antibody responses to SARS-CoV-2 in patients with COVID-19 | Quan-Xin Long, et al. @NatureMedicine 29 April 2020 | #COVID19 #کوید۱۹ #OpenAccess https://t.co/lXLwsvuFtB
Antibody Responses to SARS-CoV-2 in Patients With COVID-19 https://t.co/fB0qulBc0c
RT @RegaCarlos: PARA COLEGAS. La seroconversion ocurriría dentro de los 20 días desde el comienzo de los síntomas. Antibody responses to SA…
PARA COLEGAS. La seroconversion ocurriría dentro de los 20 días desde el comienzo de los síntomas. Antibody responses to SARS-CoV-2 in patients with COVID-19 | Nature Medicine https://t.co/r34ORz73W2
RT @FrezzaLab: Antibody responses to SARS-CoV-2 in patients with COVID-19 | Nature Medicine https://t.co/vMbpa9OZbM
RT @JezidMiranda: Antibody responses to SARS-CoV-2 in patients with COVID-19. Serological testing will be helpful for the diagnosis of susp…
RT @JezidMiranda: Antibody responses to SARS-CoV-2 in patients with COVID-19. Serological testing will be helpful for the diagnosis of susp…
RT @JezidMiranda: Antibody responses to SARS-CoV-2 in patients with COVID-19. Serological testing will be helpful for the diagnosis of susp…
Antibody responses to SARS-CoV-2 in patients with COVID-19 | Nature Medicine ccp @DrPacoMoreno1 https://t.co/wmph3rPXgo
Antibody responses to SARS-CoV-2 in patients with COVID-19 https://t.co/C5hguL9Z2j
RT @FrezzaLab: Antibody responses to SARS-CoV-2 in patients with COVID-19 | Nature Medicine https://t.co/vMbpa9OZbM
RT @Thomas_Wilckens: Antibody responses to SARS-CoV-2 in patients with #COVID_19 https://t.co/QrqTrRODvc Claims 100% seroconversion, which…
Antibody responses to SARS-CoV-2 in patients with COVID-19 | Nature Medicine https://t.co/wdPGRQXn0r
RT @Thomas_Wilckens: Antibody responses to SARS-CoV-2 in patients with #COVID_19 https://t.co/QrqTrRODvc Claims 100% seroconversion, which…
RT @Thomas_Wilckens: Antibody responses to SARS-CoV-2 in patients with #COVID_19 https://t.co/QrqTrRODvc Claims 100% seroconversion, which…
Antibody responses to SARS-CoV-2 in patients with COVID-19 https://t.co/uwFQRfeLRZ
#AyudaBiblioteca Antibody responses to SARS-CoV-2 in patients with COVID-19 https://t.co/i3H2mmNOju
RT @mackinprof: Antibody Responses to SARS-CoV-2 in Patients With COVID-19 https://t.co/han1QKUFxu
RT @Thomas_Wilckens: YOUR HELP NEEDED Any additional GOOD data out there Antibody responses to SARS-CoV-2 in patients with #COVID_19 https…
RT @mackinprof: Antibody Responses to SARS-CoV-2 in Patients With COVID-19 https://t.co/han1QKUFxu
RT @mackinprof: Antibody Responses to SARS-CoV-2 in Patients With COVID-19 https://t.co/han1QKUFxu
RT @mackinprof: Antibody Responses to SARS-CoV-2 in Patients With COVID-19 https://t.co/han1QKUFxu
Antibody Responses to SARS-CoV-2 in Patients With COVID-19 https://t.co/han1QKUFxu
RT @Thomas_Wilckens: YOUR HELP NEEDED Any additional GOOD data out there Antibody responses to SARS-CoV-2 in patients with #COVID_19 https…
YOUR HELP NEEDED Any additional GOOD data out there Antibody responses to SARS-CoV-2 in patients with #COVID_19 https://t.co/QrqTrRODvc Claims 100% seroconversion, yet there is very limited evidence some asymptomatic carriers may not convert; pls comment https://t.co/YRZqI4Ot0V https://t.co/HwuRUzEcVP
RT @Thomas_Wilckens: Antibody responses to SARS-CoV-2 in patients with #COVID_19 https://t.co/QrqTrRODvc Claims 100% seroconversion, which…
RT @Thomas_Wilckens: Antibody responses to SARS-CoV-2 in patients with #COVID_19 https://t.co/QrqTrRODvc Claims 100% seroconversion, which…
RT @macosantiago: ¡Buenas (y lógicas) noticias! Long et al. "We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19…
"Currently, the antibody responses against SARS-CoV-2 remain poorly understood and the clinical utility of serological testing is unclear" -Nature https://t.co/O6hM3pVaMb 29 April 2020
RT @macosantiago: ¡Buenas (y lógicas) noticias! Long et al. "We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19…
RT @macosantiago: ¡Buenas (y lógicas) noticias! Long et al. "We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19…
RT @macosantiago: ¡Buenas (y lógicas) noticias! Long et al. "We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19…
¡Buenas (y lógicas) noticias! Long et al. "We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19. Within 19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G". https://t.co/d2ZPYrgOB1
RT @IdiUcv: Respuestas de Anticuerpos al SARS-CoV-2 en pacientes con COVID-19. https://t.co/dZ7DRSY5nj https://t.co/iOONvrwU5o
RT @IdiUcv: Respuestas de Anticuerpos al SARS-CoV-2 en pacientes con COVID-19. https://t.co/dZ7DRSY5nj https://t.co/iOONvrwU5o
RT @IdiUcv: Respuestas de Anticuerpos al SARS-CoV-2 en pacientes con COVID-19. https://t.co/dZ7DRSY5nj https://t.co/iOONvrwU5o
RT @IdiUcv: Respuestas de Anticuerpos al SARS-CoV-2 en pacientes con COVID-19. https://t.co/dZ7DRSY5nj https://t.co/iOONvrwU5o
RT @IdiUcv: Respuestas de Anticuerpos al SARS-CoV-2 en pacientes con COVID-19. https://t.co/dZ7DRSY5nj https://t.co/iOONvrwU5o
Respuestas de Anticuerpos al SARS-CoV-2 en pacientes con COVID-19. https://t.co/dZ7DRSY5nj https://t.co/iOONvrwU5o
RT @dawso007: Long, Q., Liu, B., Deng, H. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med (2020). https://t.co/7…
RT @dawso007: Long, Q., Liu, B., Deng, H. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med (2020). https://t.co/7…
RT @dawso007: Long, Q., Liu, B., Deng, H. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med (2020). https://t.co/7…
Long, Q., Liu, B., Deng, H. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med (2020). https://t.co/7IKkWKeYCC